What is HC Wainwright's Forecast for WVE FY2028 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities researchers at HC Wainwright raised their FY2028 earnings per share estimates for Wave Life Sciences in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will earn $1.27 per share for the year, up from their previous forecast of $1.23. HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.06) per share.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.19). The business had revenue of ($7.68) million for the quarter, compared to analysts' expectations of $15.45 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Several other research analysts have also weighed in on the stock. B. Riley increased their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, November 4th. StockNews.com cut shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a research note on Wednesday. Leerink Partners increased their target price on Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Royal Bank of Canada lifted their target price on Wave Life Sciences from $7.00 to $15.00 and gave the company a "sector perform" rating in a report on Monday, October 21st. Finally, Truist Financial upped their price target on Wave Life Sciences from $17.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Wave Life Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.89.

Wave Life Sciences Stock Performance

NASDAQ WVE traded down $1.33 during trading hours on Friday, hitting $13.67. 1,432,809 shares of the company's stock were exchanged, compared to its average volume of 1,114,433. The business's 50 day moving average is $10.40 and its 200-day moving average is $7.41. Wave Life Sciences has a 12-month low of $3.50 and a 12-month high of $16.74. The firm has a market capitalization of $1.71 billion, a P/E ratio of -13.51 and a beta of -1.20.

Institutional Trading of Wave Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of WVE. Maverick Capital Ltd. raised its holdings in shares of Wave Life Sciences by 31.0% during the third quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company's stock worth $82,390,000 after purchasing an additional 2,378,159 shares during the period. Artal Group S.A. raised its stake in Wave Life Sciences by 34.7% during the first quarter. Artal Group S.A. now owns 4,051,400 shares of the company's stock worth $24,997,000 after acquiring an additional 1,044,000 shares during the period. Emerald Advisers LLC lifted its holdings in Wave Life Sciences by 15.6% in the third quarter. Emerald Advisers LLC now owns 2,881,510 shares of the company's stock worth $23,628,000 after acquiring an additional 388,280 shares during the last quarter. State Street Corp boosted its stake in Wave Life Sciences by 2.6% in the third quarter. State Street Corp now owns 2,321,248 shares of the company's stock valued at $19,034,000 after acquiring an additional 57,822 shares during the period. Finally, Emerald Mutual Fund Advisers Trust boosted its stake in Wave Life Sciences by 16.6% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 2,123,466 shares of the company's stock valued at $17,412,000 after acquiring an additional 302,528 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.

Insider Activity

In other news, CEO Paul Bolno sold 48,366 shares of the firm's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $5.78, for a total transaction of $279,555.48. Following the completion of the sale, the chief executive officer now owns 359,059 shares of the company's stock, valued at approximately $2,075,361.02. This trade represents a 11.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Plc Gsk purchased 2,791,930 shares of the business's stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company's stock, valued at $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 400,822 shares of company stock worth $5,221,768 over the last 90 days. Company insiders own 29.10% of the company's stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.